Security
CASI Pharmaceuticals, Inc. Ordinary Shares · CASIF
CASIFOTCCommon stockCurrentCIK 1962738Updated Oct 6, 2026
Name history
CASI Pharmaceuticals Holdings, Inc. · through Feb 14, 2023
CASIF price & chart
Loading TradingView…
OTC:CASIF on TradingView ↗About the company
CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CID-103 is a fully human IgG1, potentially best-in-class, clinical-stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging preclinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. In parallel, CASI is actively recruiting and dosing patients in two ongoing Phase 1/2 studies in immune thrombocytopenia (ITP) and active and chronic active renal allograft antibody-mediated rejection.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 25,650,000Source | 53,674,000Source | 75,268,000Source | 96,234,000Source |
| Property, Plant and Equipment, NetUSD | 6,968,000Source | 7,868,000Source | 9,241,000Source | 11,831,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 221,000Source | 238,000Source | 1,839,000Source | 1,063,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,632,000Source | 13,468,000Source | 17,083,000Source | 47,112,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,092,000Source | 15,345,000Source | 9,551,000Source | 12,973,000Source |
| Inventory, NetUSD | 1,598,000Source | 5,252,000Source | 15,877,000Source | 6,138,000Source |
| Assets, CurrentUSD | 13,457,000Source | 39,576,000Source | 59,344,000Source | 73,423,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,135,000Source | 2,888,000Source | 2,560,000Source | 2,975,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,548,000Source | 3,492,000Source | 2,392,000Source | 1,398,000Source |
| Other Assets, NoncurrentUSD | 740,000Source | 587,000Source | 766,000Source | 1,056,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 62,932,000Source | 51,823,000Source | 51,103,000Source | 29,302,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 1,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 722,238,000Source | 713,302,000Source | 695,785,000Source | 691,766,000Source |
| Retained Earnings (Accumulated Deficit)USD | -748,133,000Source | -700,075,000Source | -660,817,000Source | -637,160,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,785,000Source | -1,774,000Source | -1,200,000Source | -703,000Source |
| Stockholders' Equity Attributable to ParentUSD | -37,282,000Source | 1,851,000Source | 24,165,000Source | 44,574,000Source |
| Liabilities and EquityUSD | 25,650,000Source | 53,674,000Source | 75,268,000Source | 96,234,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 49,670,000Source | 36,452,000Source | 16,726,000Source | 17,005,000Source |
| Operating Lease, Liability, CurrentUSD | 1,611,000Source | 1,221,000Source | 728,000Source | 868,000Source |
| Accounts Payable, CurrentUSD | 1,065,000Source | 2,723,000Source | 4,438,000Source | 3,289,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,441,000Source | 2,535,000Source | 1,616,000Source | 476,000Source |
| Other Liabilities, NoncurrentUSD | 13,262,000Source | 15,371,000Source | 15,482,000Source | 12,297,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 726,000Source | 937,000Source | 677,000Source | 2,229,000Source |
| Long-term Debt, Current MaturitiesUSD | 19,190,000Source | 18,385,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 18,895,000Source | — |
| Redeemable Noncontrolling Interest, Equity, Common, Carrying AmountUSD | — | — | — | 22,358,000Source |
| Short-term InvestmentsUSD | — | — | 12,011,000Source | 2,763,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -48,058,000Source | -39,258,000Source | -26,259,000Source | -40,257,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,200,000Source | 1,300,000Source | 2,500,000Source | 1,200,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,986,000Source | 1,306,000Source | 7,217,000Source | 7,010,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -11,253,000Source | 5,794,000Source | -3,422,000Source | 3,170,000Source |
| Increase (Decrease) in InventoriesUSD | -2,505,000Source | -5,828,000Source | 9,739,000Source | 4,231,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -20,754,000Source | -29,224,000Source | -19,967,000Source | -21,088,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 951,000Source | 11,244,000Source | -9,673,000Source | 31,159,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 16,000Source | 223,000Source | 204,000Source | 5,612,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 278,000Source | 3,267,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,254,000Source | 15,434,000Source | -907,000Source | -3,267,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,836,000Source | -3,615,000Source | -30,029,000Source | 8,408,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,000Source | — | — | 62,000Source |
| Income Taxes Paid, NetUSD | — | — | 1,807,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 28,000Source | 1,061,000Source | 1,287,000Source | 1,211,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | — | -2,009,000Source | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | 35,000Source | 20,000Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | 474,000Source | — |
| DepreciationUSD | 1,229,000Source | 1,270,000Source | — | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | 5,325,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | -179,000Source | 1,696,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | -756,000Source | -581,000Source | -8,895,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,161,000Source | -192,000Source | 200,000Source | 3,241,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | 479,000Source | — | -2,058,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | -7,000Source | 479,000Source | — | -2,058,000Source |
| General and Administrative ExpenseUSD | 28,271,000Source | 23,577,000Source | 25,387,000Source | 23,449,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | 696,000Source | — | 8,724,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -2,187,000Source | -1,189,000Source | -48,000Source | -846,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | -81,000Source | 1,980,000Source |
| Inventory Write-downUSD | 1,149,000Source | 4,797,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -48,058,000Source | -39,258,000Source | -26,960,000Source | -41,014,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,300,000Source |
| Operating Lease, Lease IncomeUSD | — | 0Source | 0Source | 60,000Source |
| Other Nonoperating Income (Expense)USD | 20,000Source | 188,000Source | 764,000Source | 44,000Source |
| Proceeds from Stock Options ExercisedUSD | 56,000Source | 2,112,000Source | 109,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 20,712,000Source | 28,537,000Source | 33,879,000Source | 38,047,000Source |
| Cost of RevenueUSD | 10,636,000Source | 17,391,000Source | 13,827,000Source | 15,827,000Source |
| Operating Income (Loss)USD | -45,007,000Source | -39,621,000Source | -25,080,000Source | -34,032,000Source |
| Other Nonoperating Income (Expense)USD | 20,000Source | 188,000Source | 764,000Source | 44,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | -81,000Source | 1,980,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,058,000Source | -39,258,000Source | -26,960,000Source | -41,014,000Source |
| Earnings Per Share, BasicUSD per share | -2.59Source | -2.56Source | -2.02Source | -3.01Source |
| Earnings Per Share, DilutedUSD per share | -2.59Source | -2.56Source | -2.02Source | -3.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 18,538,046Source | 15,340,277Source | 13,360,185Source | 13,647,455Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,538,046Source | 15,340,277Source | 13,360,185Source | 13,647,455Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 28,000Source | 1,061,000Source | 1,287,000Source | 1,211,000Source |
| Costs and ExpensesUSD | 55,083,000Source | 50,767,000Source | 45,132,000Source | 61,312,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | — | -2,009,000Source | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | — | — | 35,000Source | 20,000Source |
| Debt Securities, Realized Gain (Loss)USD | — | — | 474,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 2,454,000Source | 1,212,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,161,000Source | -192,000Source | 200,000Source | 3,241,000Source |
| General and Administrative ExpenseUSD | 28,271,000Source | 23,577,000Source | 25,387,000Source | 23,449,000Source |
| Gross ProfitUSD | 10,076,000Source | 11,146,000Source | 20,052,000Source | 27,280,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -27,671,000Source | -32,980,000Source | 144,000Source | -12,359,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -2,187,000Source | -1,189,000Source | -48,000Source | -846,000Source |
| Interest ExpenseUSD | — | — | — | 0Source |
| Interest Income (Expense), NetUSD | — | — | 614,000Source | 127,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -840,000Source | -871,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | 1,300,000Source |
| Operating Lease, Lease IncomeUSD | — | 0Source | 0Source | 60,000Source |
| Other IncomeUSD | — | 0Source | 0Source | 48,000Source |
| Other Operating IncomeUSD | — | 2,000Source | 6,366,000Source | — |
| Research and Development ExpenseUSD | 6,308,000Source | 8,917,000Source | — | — |
| Selling and Marketing ExpenseUSD | 18,343,000Source | 17,866,000Source | 16,450,000Source | 14,326,000Source |
Filing attachments
tm2622837d2_ex99-1.htm · 6-K · 2026-08-14
Exhibit 99.1 CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results South San Francisco, California / August 14, 2026 / ACCESS NEWSWIRE / -- CASI Pharmaceuticals, Inc. (OTCQB: CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with antibody-mediated rejection (AMR) in organ transplant and various autoimmune diseases, today reported business and financial results for the first half year ended June 30, 202…
Read attachment ↗casif-20251231xex4d47.htm · 20-F · 2026-05-15
Exhibit 4.47 Equity Transfer Agreement Party A: Wuxi Zhihe Daokang II Venture Capital Partnership (Limited Partnership) (hereinafter referred to as “Zhihe Daokang” or the “Transferor”), a limited partnership legally established and validly existing under the laws of the People’s Republic of China, with Unified Social Credit Code 91320205MA27GJLN83. Party B: CASI Pharmaceuticals (China) Co., Ltd., a limited liability company legally established and validly existing under the laws of the People…
Read attachment ↗casif-20251231xex4d48.htm · 20-F · 2026-05-15
Exhibit 4.48 Execution Version Equity and Asset Transfer Agreement By and Among CASI Pharmaceuticals, Inc. Kaixin Pharmaceuticals Inc. CASI Pharmaceuticals (China) Co., Ltd. AND CASI Pharmaceuticals (Wuxi) Co., Ltd. May 9, 2025 Equity and Asset Transfer Agreement This Equity and Asset Transfer Agreement (this “Agreement”) is entered into on May 9, 2025 (the “Execution Date”) in the People’s Republic of China (the “PRC”) by and among: CASI Pharmaceuticals, Inc., an exempted company …
Read attachment ↗casif-20251231xex4d49.htm · 20-F · 2026-05-15
Exbihit 4.49 CASI PHARMACEUTICALS, INC. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Purchase Agreement”) is dated as of December 9, 2025 (the “Effective Date”), by and between CASI Pharmaceuticals, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and ETP Global III Fund LP, a Delaware limited partnership (the “Purchaser”). WHEREAS, the Company desires to issue and …
Read attachment ↗casif-20251231xex4d50.htm · 20-F · 2026-05-15
Exhibit 4.50 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND NO SALE OR DISPOSITION HEREOF MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH SUCH ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN APPLICABLE EXEMPTION THEREFROM. THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF ARE SUBJECT TO CERTAIN RESTRICTIONS O…
Read attachment ↗